- Recommendation ID
Neoadjuvant endocrine therapy in premenopausal women:- Is neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer?
- Any explanatory notes
To find out why the committee made the research recommendation on neoadjuvant endocrine therapy in premenopausal women, see rationale and impact.
Source guidance details
- Comes from guidance
- Early and locally advanced breast cancer: diagnosis and management
- Date issued
- July 2018
|Is this a recommendation for the use of a technology only in the context of research?||No|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|